| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 07/19/2000 | EP1020516A2 Leptospira vaccine antigens for the prevention of leptospirosis |
| 07/19/2000 | EP1019522A1 Compositions and methods for administering pneumococcal dna |
| 07/19/2000 | EP1019506A1 101 human secreted proteins |
| 07/19/2000 | EP1019501A1 Novel pyrimidine derivative |
| 07/19/2000 | EP1019500A2 Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons |
| 07/19/2000 | EP1019442A1 Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics |
| 07/19/2000 | EP1019435A1 Amplification of response from expressed recombinant protein |
| 07/19/2000 | EP1019409A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 07/19/2000 | EP1019396A1 Novel cycloalkyl substituted imidazoles |
| 07/19/2000 | EP1019394A1 PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| 07/19/2000 | EP1019382A1 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| 07/19/2000 | EP1019089A2 Long-acting drugs and pharmaceutical compositions comprising them |
| 07/19/2000 | EP1019087A1 Ganglioside immunostimulating complexes and uses thereof |
| 07/19/2000 | EP1019085A1 Non-anaphylactic forms of allergens and their use |
| 07/19/2000 | EP1019078A1 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis |
| 07/19/2000 | EP1019063A1 Modulation of immune responses |
| 07/19/2000 | EP1019056A1 Antiviral combinations containing the carbocyclic nucleoside 1592u89 |
| 07/19/2000 | EP1019040A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| 07/19/2000 | EP1019035A1 Il-8 receptor antagonists |
| 07/19/2000 | EP1018877A1 Low molecular weight cell, bone marrow and immune stimulants |
| 07/19/2000 | EP0821551A4 Screening assay for the identification of inhibitors of macrophage migration inhibitory factor |
| 07/19/2000 | EP0389570B2 High integrity liposomes and method of preration and use |
| 07/19/2000 | CN1260833A LAG-3 splice variants |
| 07/19/2000 | CN1260784A Quinoline derivatives as PDEIV and INF inhibitors |
| 07/19/2000 | CN1260725A Conjugate composing folic acid antagonist and carrier |
| 07/19/2000 | CN1260723A Oil in water vaccine composition |
| 07/19/2000 | CN1260721A Use of cartilage oligeomeric matrix protein for treatment of rheumatoid |
| 07/19/2000 | CN1260173A Immuno inhibitort |
| 07/19/2000 | CN1054517C Health-care wine |
| 07/19/2000 | CN1054509C Synergistic interplay of lymphokines and dsRNAs |
| 07/18/2000 | US6090914 CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| 07/18/2000 | US6090826 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
| 07/18/2000 | US6090816 Antiasthma agents |
| 07/18/2000 | US6090811 Analgesic |
| 07/18/2000 | US6090791 Method for inducing mucosal immunity |
| 07/18/2000 | US6090789 Synthesis of the breast tumor-associated antigen defined by monoclonal antibody MBr1 and uses thereof |
| 07/18/2000 | US6090782 Contacting hematopoietic cells with a stem cell proliferation inhibition amount of a peptide or polypeptide having specific amino acid sequence |
| 07/18/2000 | US6090625 Method of increasing the relative number of CD34+ cells in a cell population |
| 07/18/2000 | US6090610 Macrolide compound 0406 |
| 07/18/2000 | US6090583 Expression system in compatible host cell of a polynucleotide which produces a metalloprotease; diagnosis and treatment of asthma, disorders of leukotriene metabolism; anticarcinogenic agents; antiinflammatory/antidiabetic/antiarthritic agents |
| 07/18/2000 | US6090579 Human SDR2 cDNA clone |
| 07/18/2000 | US6090564 Amino acid sequence of human small nuclear ribonucleoprotein protein; for diagnosis, prevention and treatment of systemic lupus erythematosus |
| 07/18/2000 | US6090388 Peptide composition for prevention and treatment of HIV infection and immune disorders |
| 07/18/2000 | US6090382 Human antibodies that bind human TNFα |
| 07/18/2000 | US6090381 Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
| 07/18/2000 | CA2162689C Immunotoxins comprising gelonin and an antibody |
| 07/18/2000 | CA2132933C Soft gelatin capsule manufacture |
| 07/18/2000 | CA2108777C Modified plant viruses as vectors |
| 07/18/2000 | CA2017315C Interleukin i inhibitor |
| 07/18/2000 | CA2008183C Liquid pharmaceutical composition for piperidinoalkanol derivatives |
| 07/13/2000 | WO2000040742A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane |
| 07/13/2000 | WO2000040733A1 Human cyclic nucleotide pdes |
| 07/13/2000 | WO2000040716A2 Soluble receptor br43x2 and methods of using them for therapy |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040713A1 Method of preventing immune and hypersensitivity reactions |
| 07/13/2000 | WO2000040701A2 Non-myeloablative tolerogenic treatment |
| 07/13/2000 | WO2000040693A2 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | WO2000040612A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040597A1 Method and composition for angiogenesis inhibition |
| 07/13/2000 | WO2000040576A2 Thiopyran compounds as inhibitors of mmp |
| 07/13/2000 | WO2000040562A1 2-oxoquinoline compounds and medicinal uses thereof |
| 07/13/2000 | WO2000040263A1 Production and use of a composition containing ivig for treating diseases that are characterized by elevated extracellular fasl titers |
| 07/13/2000 | WO2000040262A1 Novel agents and methods for treatment and diagnosis of ocular disorders |
| 07/13/2000 | WO2000040261A2 Vaccination method for efficient induction of cytotoxic t lymphocyte response |
| 07/13/2000 | WO2000040260A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 07/13/2000 | WO2000040256A1 Pharmaceutical composition based on blood drawn from leukemia patients |
| 07/13/2000 | WO2000040251A1 Use of adenosine agonists in cancer therapy |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040241A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | WO2000040228A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 07/13/2000 | WO2000040225A2 Inhibition of tnf activity |
| 07/13/2000 | WO2000040219A1 Dispersible concentrate for the delivery of cyclosporin |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000027363B1 Aerosols comprising nanoparticle drugs |
| 07/13/2000 | WO2000025815A8 Novel immunoadjuvants |
| 07/13/2000 | WO2000024897B1 Cell surface molecule-induced macrophage activation |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000022121A3 Ion channels, in particular vanilloid receptor-like (vr-l) receptor |
| 07/13/2000 | WO2000018433A3 Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine |
| 07/13/2000 | WO2000015256A3 Immunostimulant emulsion |
| 07/13/2000 | WO2000014217A3 G-motif oligonucleotides and uses thereof |
| 07/13/2000 | WO2000010958A9 Vitamin d3 mimics |
| 07/13/2000 | WO2000009734A9 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 07/13/2000 | WO1999058096A9 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 07/13/2000 | DE19933939A1 Ausnutzung zelleigener Transportsysteme zum Transfer von Nukleinsäuren durch die Kernhülle Utilization of cellular transport systems for the transfer of nucleic acids by the nuclear envelope |
| 07/13/2000 | DE19900743A1 Neue komplexbildende Proteine New complexing proteins |
| 07/13/2000 | DE19900503A1 Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen mit erhöhten extrazellulären FasL-Titern, Verfahren zur prophylaktischen Eignungs- bzw. Qualitätskontrolle derselben, Verfahren zur Herstellung von Arzneimitteln zur Behandlung obiger Krankheiten mit gesteigerter Wirksamkeit Use of a composition for the manufacture of a medicament for the treatment of diseases with increased extracellular FasL titers method for the prophylactic or suitability quality control thereof, a process for the preparation of medicaments for the treatment of the above diseases with enhanced efficacy |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2358879A1 2-oxoquinoline compounds and pharmaceutical uses thereof |
| 07/13/2000 | CA2358851A1 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357874A1 Cyclic compound |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356447A1 Use of adenosine agonists in cancer therapy |
| 07/13/2000 | CA2356434A1 Non-myeloablative tolerogenic treatment |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2354638A1 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | CA2354194A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 07/12/2000 | EP1018550A2 Allergenic protein and peptides from house dust mite and uses thereof |
| 07/12/2000 | EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases |